• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pharmaceuticals

Catalent to float $400m debt offering

November 28, 2016 By Sarah Faulkner

Catalent

Catalent (NYSE:CTLT) said today that it plans to fund its acquisition of soft-gel pharmaceutical capsule manufacturer Accucaps Industries Ltd with a $400 million debt offering. The Somerset, N.J.-based company said the private placement offering of euro-dominated senior unsecured notes due in 2024 will also be used to repay some of the outstanding borrowings under its senior […]

Filed Under: Featured, Funding Roundup, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Catalent

Researchers develop human lung model

November 28, 2016 By Sarah Faulkner

(Reuters) – Czech scientists have developed a model of a functioning human lung that can be used to simulate problems like asthma or other chronic diseases and their treatments. The research group from the Brno University of Technology says its mechanical- and computer-based model of the lung can help devise treatment methods with more precision […]

Filed Under: Featured, Pharmaceuticals, Research & Development, Respiratory

Allergan expands neurological portfolio with $125m Chase Pharmaceuticals buy

November 23, 2016 By Sarah Faulkner

Allergan buys Chase Pharmaceuticals

Allergan (NYSE:AGN) said today that it acquired Chase Pharmaceuticals for an upfront payment of $125 million, expanding the Dublin-based company’s neurological portfolio. Washington, D.C.-based Chase is developing a combination therapy of an acetylcholinesterase inhibitor and a cholinergic blocker in the hopes of improving cognition in patients with Alzheimer’s disease. The acetylcholinesterase inhibitors available on the […]

Filed Under: Business/Financial News, Featured, Mergers & Acquisitions, Neurological, Pharmaceuticals Tagged With: Allergan, Chase Pharmaceuticals

Topical immunotherapy combo effective against early skin cancer

November 22, 2016 By Sarah Faulkner

Calcipotriol, 5-fluorouracil-1x1

Researchers from the Washington University School of Medicine and Harvard Medical School have shown that a combination of 2 topical drugs can trigger an immune response against precancerous skin lesions. The study was published yesterday in The Journal of Clinical Investigation. The 2 drugs, calcipotriol and 5-fluorouracil, have been in use for years – topical 5-fluorouracil is […]

Filed Under: Featured, Immunotherapy, Oncology, Pharmaceuticals, Research & Development Tagged With: Harvard University, Washington University School of Medicine

UPDATE: Mylan declines to testify at Senate committee hearing

November 22, 2016 By Sarah Faulkner

Mylan

Updated to include the Senate Judiciary Committee’s response. Mylan (NDSQ:MYL) declined to testify at a U.S. Senate committee regarding its $465 million pending settlement to deal with charges that it underpaid government healthcare programs when it misclassified its EpiPen injector as a generic. The Canonsburg, Pa.-based company penned a letter to the Senate Judiciary Committee […]

Filed Under: Drug-Device Combinations, Featured, Legal News, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Mylan

Novo Nordisk, Sanofi win FDA nods for diabetes drugs

November 22, 2016 By Sarah Faulkner

Sanofi sues Nordisk over Tresiba marketing claims in U.S.

Both Novo Nordisk (NYSE:NVO) and Sanofi (NYSE:SNY) said yesterday that they won FDA approval for pre-filled pens with drug combinations indicated for adults with Type II diabetes. Paris-based Sanofi’s Soliqua 100/33 is an injectable medicine composed of 2 diabetes drugs – insulin glargine and lixisenatide. The drug is approved for adults with Type II diabetes not controlled with less than […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance Tagged With: Novo Nordisk, Sanofi-Aventis

GSK files for FDA approval of inhaled triple-combo therapy for COPD

November 21, 2016 By Sarah Faulkner

GlaxoSmithKline

GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said today that GSK filed a regulatory submission with the FDA for the once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) for patients with chronic obstructive pulmonary disease. The triple-combo therapy includes 3 drugs: fluticasone furoate, an inhaled corticosteroid; umeclidinium, a long-acting muscarinic antagonist; vilanterol, a long-acting beta2-adrenergic agonist. The medicines […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Respiratory Tagged With: AstraZeneca plc, GlaxoSmithKline plc, Innoviva

Intarcia seeks FDA nod for 1st drug to use Medici drug delivery system

November 21, 2016 By Sarah Faulkner

Intarcia Therapeutics

Intarcia Therapeutics said today that it submitted a New Drug Application to the FDA for its injection-free ITCA 650 candidate, the 1st drug to use Intarcia’s Medici drug delivery system to treat Type II diabetes. The ITCA 650 enables subcutaneous delivery of exenatide using a match-sized osmotic pump placed under the skin in an in-office procedure. With […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Pharmaceuticals, Regulatory/Compliance Tagged With: Intarcia Therapeutics

Restoring blood vessels to tumor cells aids delivery of chemotherapy

November 18, 2016 By Sarah Faulkner

Researchers from the Flanders Institute for Biotechnology in Belgium say they have found a way to repair dysfunctional blood vessels which allow cancer cells to escape from the blood stream and reach other organs, and which play a vital role in cancer metastasis. In a study published in Cancer Cell, researchers describe how they manipulated the blood […]

Filed Under: Featured, Oncology, Pharmaceuticals, Research & Development Tagged With: Flanders Institute of Biotechnology

Mallinckrodt touts data for Ofirmev injected acetaminophen

November 18, 2016 By Sarah Faulkner

Mallinckrodt Pharmaceuticals

Mallinckrodt Pharmaceuticals (NYSE:MNK) today released results from a clinical pharmacokinetic study evaluating the effect of IV morphine on the absorption of oral acetaminophen, touting the effectiveness of its Ofirmev IV administered acetaminophen over orally administered acetaminophen in adjunct to IV morphine. The results were presented at this year’s Pain Medicine Meeting of the American Society of […]

Filed Under: Clinical Trials, Featured, Pain Management, Pharmaceuticals, Surgical Tagged With: Mallinckrodt Pharmaceuticals

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 201
  • Page 202
  • Page 203
  • Page 204
  • Page 205
  • Page 206
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS